Clinical Study

A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing The Efficacy And Safety Of Repeated Biweekly Infusions Of Neogaa (Gz402666) And Alglucosidase Alfa In Treatment-Naïve Patients With Late Onset Pompe Disease

Posted Date: Oct 6, 2017

  • Investigator: Hani Kushlaf
  • Co-Investigator: Alecia Corcoran
  • Specialties: Neurology, Neuromuscular Disorders
  • Type of Study: Drug

The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease), as well as pharmacokinetics (breakdown, use and removal from the body of the study drug (neoGAA) of the study drug (neoGAA) compared to Myozyme®/Lumizyme® (


To Be Considered For This Study, You Must Have Been Diagnosed With Late Onset Pompe Disease (Acid A Glucosidase (Gaa) Deficiency) And Have Never Received The Study Drug (Neogaa), Myozyme®/Lumizyme® Or Other Investigational Drug In A Clinical Study For Yo


Abnormal Emg, Myopathy, Pompe, Elevated Liver Enzymes, Enzyme Replacement Therapy

For More Information:

Alecia Corcoran
(513) 558-0039

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.